MX2020013243A - Anticuerpos anti-il-22, fragmentos de anticuerpo, sus inmunoconjugados y usos de los mismos. - Google Patents
Anticuerpos anti-il-22, fragmentos de anticuerpo, sus inmunoconjugados y usos de los mismos.Info
- Publication number
- MX2020013243A MX2020013243A MX2020013243A MX2020013243A MX2020013243A MX 2020013243 A MX2020013243 A MX 2020013243A MX 2020013243 A MX2020013243 A MX 2020013243A MX 2020013243 A MX2020013243 A MX 2020013243A MX 2020013243 A MX2020013243 A MX 2020013243A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- antibody
- antibody fragments
- immunoconjugates
- antibody fragment
- Prior art date
Links
- 102000008394 Immunoglobulin Fragments Human genes 0.000 title abstract 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 title abstract 4
- 229940127121 immunoconjugate Drugs 0.000 title 1
- 108010074109 interleukin-22 Proteins 0.000 abstract 2
- 101001010626 Homo sapiens Interleukin-22 Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un anticuerpo o fragmento de anticuerpo anti-IL-22 que se une tanto a IL-22 humana como a una IL-22 de mamífero, y también anticuerpos y fragmentos de anticuerpo anti-IL-22 modificados; también se proveen composiciones farmacéuticas y kits que comprenden 5 el anticuerpo o fragmento de anticuerpo; también se proveen métodos de tratamiento de varias afecciones y enfermedades mediadas por IL-22.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862680698P | 2018-06-05 | 2018-06-05 | |
US201862752567P | 2018-10-30 | 2018-10-30 | |
PCT/US2019/035395 WO2019236585A1 (en) | 2018-06-05 | 2019-06-04 | Anti-il-22 antibodies, antibody fragments, their immunoconjugates and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020013243A true MX2020013243A (es) | 2021-05-12 |
Family
ID=68769207
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020013243A MX2020013243A (es) | 2018-06-05 | 2019-06-04 | Anticuerpos anti-il-22, fragmentos de anticuerpo, sus inmunoconjugados y usos de los mismos. |
Country Status (12)
Country | Link |
---|---|
US (2) | US11834472B2 (es) |
EP (1) | EP3802596A4 (es) |
JP (2) | JP7473977B2 (es) |
KR (1) | KR20210019464A (es) |
CN (1) | CN112292396A (es) |
AU (1) | AU2019282626A1 (es) |
CA (1) | CA3102391A1 (es) |
IL (1) | IL279086A (es) |
MX (1) | MX2020013243A (es) |
SG (1) | SG11202012014UA (es) |
TW (1) | TW202000697A (es) |
WO (1) | WO2019236585A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023110942A1 (en) | 2021-12-14 | 2023-06-22 | Charité-Universitätsmedizin Berlin | Prevention of impaired fracture healing |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6551799B2 (en) | 1999-12-07 | 2003-04-22 | Genentech, Inc. | Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders |
US6274710B1 (en) | 1998-10-26 | 2001-08-14 | Ludwig Institute For Cancer Research | Antibodies which specifically bind T Cell inducible factors (TIFs) |
US6939545B2 (en) | 1999-04-28 | 2005-09-06 | Genetics Institute, Llc | Composition and method for treating inflammatory disorders |
JP2005510451A (ja) | 2001-02-23 | 2005-04-21 | ジェネティクス インスティテュート,エルエルシー | 炎症性障害を治療するための組成物及び方法 |
EP1546358A4 (en) * | 2002-03-22 | 2006-06-07 | Zymogenetics Inc | ANTI-IL-TIF ANTIBODIES AND METHOD FOR USE ON INFLAMMATION |
KR20060022289A (ko) | 2003-06-23 | 2006-03-09 | 제네틱스 인스티튜트, 엘엘씨 | 인터류킨-22 에 대한 항체 및 그의 용도 |
BRPI0516975A (pt) | 2004-10-22 | 2008-09-30 | Zymogenetics Inc | anticorpo ou seu fragmento de ligação a antìgeno, composição farmacêutica, imunoconjugado, hibridoma, anticorpo monoclonal, e, uso de um anticorpo ou seu fragmento de ligação a antìgeno |
CN100515491C (zh) | 2005-01-04 | 2009-07-22 | 健能隆医药技术(上海)有限公司 | 白介素-22的医药用途 |
NZ621483A (en) * | 2005-12-02 | 2015-10-30 | Genentech Inc | Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r |
AU2013200914B2 (en) * | 2005-12-02 | 2016-01-14 | Genentech, Inc. | Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to IL-22 and IL-22R |
TWI417301B (zh) | 2006-02-21 | 2013-12-01 | Wyeth Corp | 對抗人類介白素-22(il-22)之抗體及其用途 |
TW200744634A (en) * | 2006-02-21 | 2007-12-16 | Wyeth Corp | Methods of using antibodies against human IL-22 |
EP2658970B1 (en) | 2010-12-31 | 2016-09-28 | Bioatla LLC | Express humanization of antibodies |
CN103182072B (zh) | 2011-12-27 | 2017-05-03 | 健能隆医药技术(上海)有限公司 | 白介素‑22在治疗和预防神经损伤疾病或神经退行性疾病中的用途 |
DK2970422T3 (en) | 2013-03-15 | 2018-07-16 | Hoffmann La Roche | IL-22 POLYPEPTIDES AND IL-22 FC-FUSION PROTEINS AND METHODS OF USE |
CN107580603A (zh) | 2015-02-24 | 2018-01-12 | 生物蛋白有限公司 | 条件活性生物蛋白 |
GB201612337D0 (en) | 2016-07-15 | 2016-08-31 | Argen-X N V | Ant-il-22r antibodies |
-
2019
- 2019-06-04 AU AU2019282626A patent/AU2019282626A1/en active Pending
- 2019-06-04 EP EP19816016.0A patent/EP3802596A4/en active Pending
- 2019-06-04 SG SG11202012014UA patent/SG11202012014UA/en unknown
- 2019-06-04 KR KR1020207038016A patent/KR20210019464A/ko active Search and Examination
- 2019-06-04 MX MX2020013243A patent/MX2020013243A/es unknown
- 2019-06-04 WO PCT/US2019/035395 patent/WO2019236585A1/en active Application Filing
- 2019-06-04 US US16/972,357 patent/US11834472B2/en active Active
- 2019-06-04 CN CN201980038826.8A patent/CN112292396A/zh active Pending
- 2019-06-04 JP JP2021518032A patent/JP7473977B2/ja active Active
- 2019-06-04 CA CA3102391A patent/CA3102391A1/en active Pending
- 2019-06-05 TW TW108119613A patent/TW202000697A/zh unknown
-
2020
- 2020-11-30 IL IL279086A patent/IL279086A/en unknown
-
2023
- 2023-10-23 US US18/491,898 patent/US20240141035A1/en active Pending
-
2024
- 2024-02-16 JP JP2024021786A patent/JP2024059724A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3102391A1 (en) | 2019-12-12 |
IL279086A (en) | 2021-01-31 |
JP7473977B2 (ja) | 2024-04-24 |
KR20210019464A (ko) | 2021-02-22 |
JP2021527122A (ja) | 2021-10-11 |
TW202000697A (zh) | 2020-01-01 |
SG11202012014UA (en) | 2021-01-28 |
CN112292396A (zh) | 2021-01-29 |
US11834472B2 (en) | 2023-12-05 |
US20210230263A1 (en) | 2021-07-29 |
JP2024059724A (ja) | 2024-05-01 |
EP3802596A4 (en) | 2022-07-20 |
US20240141035A1 (en) | 2024-05-02 |
WO2019236585A1 (en) | 2019-12-12 |
AU2019282626A1 (en) | 2021-01-07 |
EP3802596A1 (en) | 2021-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202005259B (en) | Anti-ctla4 antibodies and methods of making and using the same | |
ZA202004730B (en) | Anti-claudin 18.2 antibodies and uses thereof | |
MX2020009366A (es) | Anticuerpos anti-cd73 y usos de los mismos. | |
EP4248996A3 (en) | Anti-trem2 antibodies and methods of use thereof | |
SA519402358B1 (ar) | Ccr7 مترافقات عقار جسم مضاد لـ | |
WO2019224716A3 (en) | Antibodies specific for gucy2c and uses thereof | |
MX2021004808A (es) | Anticuerpos contra la epcam, anticuerpos activables e inmunoconjugados y usos de estos. | |
MY185813A (en) | Factor xi antibodies and methods of use | |
AU2015347015A8 (en) | Antibody drug conjugates | |
MX2021000392A (es) | Anticuerpos anti-mesotelina. | |
MX2023000738A (es) | Proteinas de union a antigeno que activan el receptor de leptina. | |
MX2021008958A (es) | Proteínas de unión a antígeno del receptor gamma anti-il2. | |
MX2020008736A (es) | Formulaciones de anticuerpos b7-h4. | |
MX2023004333A (es) | Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo. | |
PH12018502275A1 (en) | Interferon beta antibodies and uses thereof | |
EP4414034A3 (en) | Antibodies specific for cd3 and uses thereof | |
MX2020008122A (es) | Anticuerpos anti-pd-1. | |
MX2022007231A (es) | Anticuerpos anti-mertk y metodos de uso de los mismos. | |
EA202191769A1 (ru) | Тубулизины и конъюгаты белок-тубулизин | |
MX2021004454A (es) | Anticuerpos anti-sinucleina. | |
MX2019009498A (es) | Anticuerpos mimeticos de fgf21 y usos de los mismos. | |
MX2021010116A (es) | Anticuerpo anti-pd-l1 y uso de este. | |
PH12019500342A1 (en) | Antibody or an antigen-binding fragment thereof capable of binding to a human receptor of interleukin-6 | |
MX2023009681A (es) | Composiciones de anticuerpos anti-tl1a y metodos de tratamiento en el pulmon. | |
MX2020013243A (es) | Anticuerpos anti-il-22, fragmentos de anticuerpo, sus inmunoconjugados y usos de los mismos. |